Aileron Therapeutics(ALRN) Prnewswire·2025-01-10 16:30Core Viewpoint - Rein Therapeutics has rebranded from Aileron Therapeutics to emphasize its commitment to developing therapies for orphan pulmonary and fibrosis indications, with shares set to trade under the new Nasdaq symbol "RNTX" starting January 13, 2025 [1][2] Recent Clinical Achievements - The lead candidate, LTI-03, has shown positive topline data from a Phase 1b clinical trial, indicating safety and tolerability in patients with idiopathic pulmonary fibrosis (IPF), with four biomarkers demonstrating statistical significance [3] - High dose LTI-03 (5 mg BID) maintained a favorable safety profile, while five biomarkers showed dose dependence in the trial [3] Corporate Highlights - In March 2024, Brian Windsor was appointed as CEO, reinforcing the company's focus on first-in-class therapies for orphan pulmonary and fibrosis indications [6] - In May 2024, the company raised approximately $17.7 million through an underwritten registered direct offering of common stock and accompanying warrants [6] Strategic Objectives - A Phase 2 clinical trial for LTI-03 is anticipated to begin in the first half of 2025, targeting idiopathic pulmonary fibrosis [5][6] - The second product candidate, LTI-01, has completed Phase 1b and Phase 2a trials for loculated pleural effusions and has received Orphan Drug Designation and Fast Track Designation in the U.S. [5][6]